Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · IEX Real-Time Price · USD
1.04
-0.02 (-1.89%)
May 18, 2022 11:32 AM EDT - Market open
Market Cap48.42M
Revenue (ttm)n/a
Net Income (ttm)-39.96M
Shares Out46.55M
EPS (ttm)-1.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume95,094
Open1.08
Previous Close1.06
Day's Range1.03 - 1.09
52-Week Range1.01 - 9.54
Beta0.99
AnalystsBuy
Price Target6.50 (+525.0%)
Earnings DateMay 5, 2022

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of ...

IndustryBiotechnology
IPO DateMar 23, 2016
CEORichard Miller
Employees28
Stock ExchangeNASDAQ
Ticker SymbolCRVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is 6.5, which is an increase of 525.00% from the latest price.

Price Target
$6.5
(525.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas

1 week ago - GlobeNewsWire

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

Company to host a webcast at 9:00am ET / 6:00am PT Company to host a webcast at 9:00am ET / 6:00am PT

3 weeks ago - GlobeNewsWire

Best Penny Stocks To Watch In April? 3 Insiders Are Buying Now

Penny stocks insiders are buying right now. The post Best Penny Stocks To Watch In April?

Other symbols:CREXTMC
1 month ago - PennyStocks

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT

2 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on M...

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

2 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor C...

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in...

4 months ago - GlobeNewsWire

New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Diseas...

Data Presented in Poster Presentation at American Society of Hematology Annual Meeting Data Presented in Poster Presentation at American Society of Hematology Annual Meeting

5 months ago - GlobeNewsWire

Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Socie...

Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy

6 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial res...

6 months ago - GlobeNewsWire

5 Penny Stocks To Watch For November With Potential Biotech Catalysts

Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Inform...

Other symbols:AGENLQDAPHASTNXP
6 months ago - PennyStocks

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of...

CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals

6 months ago - GlobeNewsWire

Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818

JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd.

6 months ago - PRNewsWire

Hot Penny Stocks to Buy This Week? 3 For Your October Watchlist

Making a list of penny stocks to buy in October? Check these three out The post Hot Penny Stocks to Buy This Week?

Other symbols:GRNQRWLK
7 months ago - PennyStocks

4 Buy-Ranked Stocks that Soared Over 20% in the Past Week

The market remains on its toes as investors digest the ton of information hitting us about now.

Other symbols:CVLGHRI
7 months ago - Zacks Investment Research

3 Biotech Stocks That Could Make You Filthy Rich

These three low-priced cancer stocks could be grossly undervalued.

Other symbols:ADAPVSTM
7 months ago - The Motley Fool

Why Corvus Pharmaceuticals Stock Is Down Today

Profit taking appears to be in full effect today with this small-cap biotech.

7 months ago - The Motley Fool

Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has shared data from the Phase 3 mupadolimab COVID-19 trial. The data from 40 patients suggested improvement in the primary and key secondary endpoints in patie...

7 months ago - Benzinga

Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab t...

7 months ago - GlobeNewsWire

Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options

Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Best Penny Stocks to Buy Right Now? 3 You Need to Know About

These penny stocks shot up today, are they worth watching or not? The post Best Penny Stocks to Buy Right Now?

Other symbols:CEIREED
8 months ago - PennyStocks

What's Going On With Corvus Pharmaceuticals Stock Today?

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC (NASDAQ: AZN) for pati...

8 months ago - Benzinga

12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (CRVS) as Shares Rocket

Corvus Pharmaceuticals (CRVS) stock is rising higher on heavy trading volume Friday despite a lack of news from the company. The post 12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (...

8 months ago - InvestorPlace

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will partici...

8 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021 Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021

9 months ago - GlobeNewsWire

Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)

Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...

9 months ago - Zacks Investment Research